Portfolio Prioritization: Unlock Value in the Pipeline
A new CEO at a development-stage biotech company with market capitalization of $300-$400 M needed to make strategic decisions about which of 10+ early stage portfolio products to develop. At the time, the company had the opportunity to move up to three products into pivotal trials, and the CEO wanted an independent judgment on what funding decisions the organization could make.
© 2020 SOURCE EXPLORER®. All rights reserved.